Overall, the presence of oncogenic driver mutations in key lung cancer targets, such as activating mutations in EGFR, ERBB2, KRAS, MET, as well as ALK, RET, and ROS1 fusions, had no impact on patient progression (HR [95% CI] =0.87 [0.55-1.38], P=0.56, Supplementary Figure 4A). Here, KRAS is linked to lung cancer.